Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Pre-Clinical Models and Potential Novel Therapies for Glioblastomas

Michelle Zalles  1   2 , Rheal A. Towner  1   2
Waldemar Debinski  1
, editors.
In: Gliomas [Internet]. Brisbane (AU): Exon Publications; 2021 Apr 30. Chapter 1.
Affiliations
Review

Pre-Clinical Models and Potential Novel Therapies for Glioblastomas

Michelle Zalles et al.

Excerpt

Glioblastoma is an extremely aggressive form of cancer most commonly derived from neural stem cells, astrocytes, and oligodendrocytes that occurs in the brain and has a 5-year survival rate of 6.7%. These gliomas have an incidence of 3.19 cases per 100,000 person and are assigned grade IV according to the World Health Organization classification of brain tumors. Current approved therapies include surgical resection followed by a combination of radiation and chemotherapy with temozolomide, and more recently tumor-treating (TT) fields. However, there are many limitations with the current treatment strategies due to several resistance mechanisms varying from low concentrations of chemotherapeutics crossing the blood brain barrier to increased risk of temozolomide resistance in a sub-set of patients. In recent years, novel therapies and delivery systems have been developed to overcome these limitations. In this chapter, we discuss pre-clinical assessments and the evaluation of potential, promising therapeutics in xenograft models for glioblastoma using advanced magnetic resonance imaging techniques.

PubMed Disclaimer

References

    1. Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1985–96. https://doi.org/10.1158/1055-9965.EPI-14-0275. - DOI - PMC - PubMed
    1. Nayak L, Reardon DA. High-grade Gliomas. Continuum. Neuro-oncology. 2017;23(6):1548–63. https://doi.org/10.1212/CON.0000000000000554. - DOI - PubMed
    1. Yao M, Li S, Wu X, Diao S, Zhang G, He H, et al. Cellular origin of glioblastoma and its implication in precision therapy. Cell Mol Immunol. 2018;15(8):737–9. https://doi.org/10.1038/cmi.2017.159. - DOI - PMC - PubMed
    1. Tamimi AF, Juweid M. Epidemiology and Outcome of Glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma. Brisbane (AU); 2017. https://doi.org/10.15586/codon.glioblastoma.2017.ch8. - DOI - PubMed
    1. Eder K, Kalman B. Molecular heterogeneity of glioblastoma and its clinical relevance. Pathol Oncol Res. 2014;20(4):777–87. https://doi.org/10.1007/s12253-014-9833-3. - DOI - PubMed

LinkOut - more resources